SPAM1 Small Molecule PAC1-R Modulator for Barrier-Crossing PACAP Regulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The neuropeptide PACAP, crucial for regulating nervous, endocrine, and immune systems, has limited pharmaceutical development due to poor stability and difficulty crossing biological barriers, hindering its potential as an anti-aging agent.
Innovation Solution
A small molecule compound SPAM1, specifically designed as a PAC1-R allosteric modulator, is synthesized to up-regulate PACAP and PAC1-R expression, overcoming biological barrier limitations and acting on target organs in a feedback-positive manner.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PACAP is used directly as a drug, then it can regulate nervous, endocrine and immune systems, but it has extremely poor stability in vivo with a half-life of less than 2 minutes
Solution Approach 1:
The patent uses small molecule compounds (SPAM1 and its derivatives) as intermediary substances that indirectly regulate PACAP/PAC1-R signaling rather than administering PACAP directly. These small molecules act as mediators that can cross biological barriers and modulate the PACAP pathway, solving the stability problem while maintaining therapeutic effectiveness.
Solution Approach 2:
Instead of using the original PACAP peptide, the patent synthesizes small molecule compounds that copy or mimic the biological effects of PACAP by modulating the PAC1-R receptor. These synthetic molecules (SPAM1 and derivatives) replicate the desired physiological outcomes without the stability limitations of the native peptide.
2Reliability
If PACAP is used directly as a drug, then it can mediate important physiological functions, but it has limited function of crossing biological barriers
Solution Approach 1:
The patent changes the physical and chemical parameters of the therapeutic agent from a large peptide (PACAP) to small molecules (SPAM1 and derivatives). This parameter change in molecular size and structure enables the compounds to cross biological barriers such as the blood-brain barrier, while still maintaining the ability to modulate PAC1-R receptors and achieve therapeutic effects.
3Stability of the object's composition
If small molecule compounds are designed to target PAC1-R, then they can overcome stability and barrier crossing limitations, but they require precise structural design and synthesis
Solution Approach 1:
The patent focuses on designing small molecules with specific local structural features that are critical for PAC1-R binding. By identifying and optimizing key structural elements (such as the core scaffold and substituent positions), the patent achieves effective target engagement while maintaining reasonable synthetic feasibility through systematic structure-activity relationship studies.
Data Source
AI summary
A small molecule compound SPAM1 for up-regulating neuropeptide PACAP and receptor PAC1-R thereof, a method for preparing the same and use of the same; the SPAM1 has a structure of formula (I), wherein R=none, H2O or HCl; SPAM1 has small molecular weight, and can efficiently cross biological barriers including a blood-brain barrier, a blood-testis barrier etc; SPAM1 up-regulates the expression of the neurotransmitter/neuromodulator PACAP secreted by hypothalamus-pituitary and the specific receptor thereof, and acts on the glands downstream of the gonadal axis and the adrenal axis, thereby exerting comprehensive regulation effects; and SPAM1 specifically targets the PAC1-R1, and only acts on cells and tissues of nervous and endocrine systems naturally expressing the PAC1-R, thereby producing fewer side effects. Accordingly, SPAM1 is a novel small molecule compound medicament for effectively treating and preventing function decline and disorders of nervous, endocrine and immune systems closely related to neuropeptide PACAP.